1	DAVID C. SHONKA		
2	Acting General Counsel AMY C. HOCEVAR (Ohio Bar #0075510)		
3	ahocevar@ftc.gov NICOLE J. GUINTO (Ohio Bar #0089319)		
4	nguinto@ftc.gov DANA C. BARRAGATE (Ohio Bar #006574	18)	
5	dbarragate@ftc.gov Federal Trade Commission		
	1111 Superior Avenue, Suite 200 Cleveland, Ohio 44114		
6	Hocevar Phone: (216) 263-3409 Guinto Phone: (216) 263-3435		
7	Barragate Phone: (216) 263-3402 Fax: (216) 263-3426		
8			
9	Local Counsel THOMAS J. SYTA (California Bar #116286)		
10	Federal Trade Commission		
11	10877 Wilshire Blvd., Suite 700 Los Angeles, CA 90024		
12	Phone: (310) 824-4343 Fax: (310) 824-4380		
13	Attorneys for Plaintiff		
14	FEDERAL TRADE COMMISSION		
15	UNITED STATES I	DISTRICT COURT	
16	FOR THE CENTRAL DIST	TRICT OF CALIFORNIA	
17	FEDERAL TRADE COMMISSION,	Case No. 8:16-cv-2147	
18	Plaintiff,	COMPLAINT FOR	
19	v.	PERMANENT INJUNCTION AND OTHER EQUITABLE	
20	AURA LABS, INC., a corporation, also	RELIEF	
21	d/b/a AuraLifé and AuraWare, and		
22	RYAN ARCHDEACON, individually and as an officer of AURA LABS, INC.,		
23	Defendants.		
24			
25			
26			
27			

Plaintiff, the Federal Trade Commission ("FTC"), for its Complaint alleges:

1. The FTC brings this action under Section 13(b) of the Federal Trade Commission Act ("FTC Act"), 15 U.S.C. § 53(b), to obtain permanent injunctive relief, rescission or reformation of contracts, restitution, the refund of monies paid, disgorgement of ill-gotten monies, and other equitable relief for Defendants' acts or practices in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52, in connection with the advertising, marketing, distribution, and sale of a mobile device software application called Instant Blood Pressure (the "Instant Blood Pressure App").

JURISDICTION AND VENUE

- 2. This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1337(a), and 1345, and 15 U.S.C. §§ 45(a) and 53(b).
- 3. Venue is proper in this district under 28 U.S.C. § 1391(b)(1), (b)(2), (b)(3), (c)(1), (c)(2), and (d), and 15 U.S.C. § 53(b).

PLAINTIFF

- 4. The FTC is an independent agency of the United States Government created by statute. 15 U.S.C. §§ 41-58. The FTC enforces Section 5(a) of the FTC Act, 15 U.S.C. § 45(a), which prohibits unfair or deceptive acts or practices in or affecting commerce. The FTC also enforces Section 12 of the FTC Act, 15 U.S.C. § 52, which prohibits false advertisements for food, drugs, devices, services, or cosmetics in or affecting commerce.
- 5. The FTC is authorized to initiate federal district court proceedings, by its own attorneys, to enjoin violations of the FTC Act and to secure such equitable relief as may be appropriate in each case, including rescission or reformation of contracts, restitution, the refund of monies paid, and the disgorgement of ill-gotten monies. 15 U.S.C. §§ 53(b) and 56(a)(2)(A).

DEFENDANTS

- 6. Defendant Aura Labs, Inc. (Aura), also doing business as AuraLife and AuraWare, is a Delaware corporation with its principal place of business at 4343 Von Karman Avenue, Suite 150J, Newport Beach, California. Aura transacts or has transacted business in this district and throughout the United States. At all times material to this Complaint, acting alone or in concert with others, Aura has advertised, marketed, distributed or sold the Instant Blood Pressure App to consumers throughout the United States.
- 7. Defendant Ryan Archdeacon is the Chief Executive Officer and President of Aura. He is also a member of the company's Board of Directors and is the largest shareholder. At all times material to this Complaint, acting alone or in concert with others, he has formulated, directed, had the authority to control, or participated in the acts and practices set forth in this Complaint. Among other things, he actively participated in the development and evaluation of the purported substantiation for the challenged claims, and he is responsible for creating, evaluating, and approving advertisements and promotional materials. Defendant Archdeacon, in connection with the matters alleged herein, transacts or has transacted business in this district and throughout the United States.

COMMERCE

8. At all times material to this Complaint, Defendants have maintained a substantial course of trade in or affecting commerce, as "commerce" is defined in Section 4 of the FTC Act, 15 U.S.C. § 44.

DEFENDANTS' BUSINESS ACTIVITIES

9. The Instant Blood Pressure App is a mobile device software application that uses mathematical algorithms, mobile device measurements, and consumer inputs (gender, birthdate, height, weight) for the purported purpose of blood pressure measurement.


- 10. The Instant Blood Pressure App was available for purchase and download over the Internet through mobile device software distribution platforms. From at least June 2014 to at least July 31, 2015, Defendants advertised and sold the Instant Blood Pressure App through the Apple App Store or the Google Play marketplace for \$3.99 or \$4.99.
- 11. The Instant Blood Pressure App asks consumers to input their gender, age, weight and height when ready to use the App.
- 12. Consumers are instructed to remove any outer clothing, place their right index finger over the rear camera lens and light, place the bottom of the mobile device against the left side of their chest while maintaining their finger position, and hold this position until the measurement is complete and the results for systolic and diastolic blood pressure measurements are displayed.
- 13. Sales of the Instant Blood Pressure App between its launch in June 2014 and June 21, 2015 totaled over \$600,000.


ADVERTISING CLAIMS

14. To induce consumers to purchase the Instant Blood Pressure App,
Defendants have disseminated or caused to be disseminated advertisements for the
Instant Blood Pressure App, including but not necessarily limited to the following
statements and depictions:


A. Selected Screenshots from the Apple App Store (April 16, 2015)








B. Selected Screenshots from iOS version of the App (April 16, 2015)



C. Selected Screenshots from Mobile Website Capture (April 16, 2015)





Pretty cool! An app that is necessary & convenient. I like that I can use it to measure my BP and someone else's BP...it is not just tied to me.

— Marcie

This is such a smart idea that will benefit many of us in monitoring our health in an easy and convenient way.

— Greg & Dlane

15. Although Defendants represent that the Instant Blood Pressure App measures blood pressure as accurately as a traditional blood pressure cuff and serves as a replacement for a traditional cuff, in fact, studies demonstrate clinically

and statistically significant deviations between the App's measurements and those from a traditional blood pressure cuff.

CONSUMER ENDORSEMENTS

16. Defendant Ryan Archdeacon left the following review of the Instant Blood Pressure App in the Apple App Store:

Great start ★★★★

by ARCHIE1986 – Version – 1.0.1 – Jun 11, 2014

This app is a breakthrough for blood pressure monitoring. There are some kinks to work out and you do need to pay close attention to the directions in order to get a successful measurement but all-in-all it's a breakthrough product. For those having connection problems, consider trying again. I have experienced a similar issue. It is also great that the developer is committed to continual improvements.

This is a great start!!!

- 17. That the review was left by the Chief Executive Officer and President of Aura was not disclosed to consumers and would materially affect the weight and credibility consumers assigned to the endorsement.
- 18. At times material to this Complaint, the **What People Think** portion of Defendants' website contained three endorsements, including the following endorsement from relatives of Aura's Chairman of the Board and co-founder Aaron Giroux:

This is such a smart idea that will benefit many of us in monitoring our health in an easy and convenient way.

19. That the endorsement was left by relatives of Aura's Chairman of the Board and co-founder Aaron Giroux was not disclosed to consumers and would materially affect the weight and credibility consumers assigned to the endorsement.

VIOLATIONS OF THE FTC ACT

- 20. Section 5(a) of the FTC Act, 15 U.S.C. § 45(a), prohibits "unfair or deceptive acts or practices in or affecting commerce."
- 21. Misrepresentations or deceptive omissions of material fact constitute deceptive acts or practices prohibited by Section 5(a) of the FTC Act.
- 22. Section 12 of the FTC Act, 15 U.S.C. § 52, prohibits the dissemination of any false advertisement in or affecting commerce for the purpose of inducing, or which is likely to induce, the purchase of food, drugs, devices, services or cosmetics. For the purposes of Section 12 of the FTC Act, 15 U.S.C. § 52, the Instant Blood Pressure App is a "device" as defined in Section 15(d) of the FTC Act, 15 U.S.C. § 55(d).

COUNT I

FALSE OR UNSUBSTANTIATED CLAIMS REGARDING BLOOD PRESSURE

- 23. Through the means described in Paragraphs 14-15, Defendants have represented, directly or indirectly, expressly or by implication, that the Instant Blood Pressure App:
 - A. Serves as a replacement for a traditional blood pressure cuff; and
 - B. Measures blood pressure as accurately as a traditional blood pressure cuff.
- 24. The representations set forth in Paragraph 23 are false or misleading or were not substantiated at the time the representations were made.
- 25. Therefore, the making of the representations as set forth in Paragraph 23 of this Complaint constitutes a deceptive act or practice and the making of false advertisements, in or affecting commerce, in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52.

COUNT II

DECEPTIVE USE OF ENDORSEMENTS

- 26. Through the means described in Paragraphs 16-19, Defendants represented, directly or indirectly, expressly or by implication, that the consumer endorsements featured on the instantbloodpressure.com website, the Apple App Store, and in other marketing were independent endorsements reflecting the views of ordinary consumers of the Instant Blood Pressure App.
- 27. In truth and in fact, certain endorsements of the Instant Blood Pressure App were not independent endorsements reflecting the views of ordinary consumers, but were endorsements by employees of Aura or their relatives.
- 28. Therefore, the making of the representation as set forth in Paragraph 26 of the Complaint constitutes a deceptive act or practice, in or affecting commerce, in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52.

COUNT III

FAILURE TO DISCLOSE MATERIAL CONNECTIONS

- 29. Through the means described in Paragraphs 16-19, Defendants represented, directly or indirectly, expressly or by implication, that the consumer endorsements featured on the instantbloodpressure.com website, the Apple App Store, and in other marketing were endorsements from persons who had used the Instant Blood Pressure App.
- 30. Defendants failed to disclose, or disclose adequately, that certain endorsements were by employees of Aura or their relatives. This fact would be material to consumers in their decision to purchase the Instant Blood Pressure App.
- 31. The failure to disclose this fact, in light of the representations made, was, and is, a deceptive act or practice, in or affecting commerce, in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52.

CONSUMER INJURY

32. Consumers have suffered and will continue to suffer substantial injury as a result of Defendants' violations of the FTC Act. In addition, Defendants have been unjustly enriched as a result of their unlawful acts or practices. Absent injunctive relief by this Court, Defendants are likely to continue to injure consumers, reap unjust enrichment, and harm the public interest.

THIS COURT'S POWER TO GRANT RELIEF

33. Section 13(b) of the FTC Act, 15 U.S.C. § 53(b), empowers this Court to grant injunctive and such other relief as the Court may deem appropriate to halt and redress violations of any provision of law enforced by the FTC. The Court, in the exercise of its equitable jurisdiction, may award ancillary relief, including rescission or reformation of contracts, restitution, the refund of monies paid, and the disgorgement of ill-gotten monies, to prevent and remedy any violation of any provision of law enforced by the FTC.

PRAYER FOR RELIEF

Wherefore, Plaintiff FTC, pursuant to Section 13(b) of the FTC Act, 15 U.S.C. § 53(b), and the Court's own equitable powers, requests that the Court:

- A. Enter a permanent injunction to prevent future violations of the FTC Act by Defendants;
- B. Award such relief as the Court finds necessary to redress injury to consumers resulting from Defendants' violations of the FTC Act, including but not limited to, rescission or reformation of contracts, restitution, the refund of monies paid, and the disgorgement of ill-gotten monies; and
- C. Award Plaintiff the costs of bringing this action, as well as such other and additional relief as the Court may determine to be just and proper.

1		Respectfully submitted,
2		D
3		DAVID C. SHONKA Acting General Counsel
4		
5	Dated: December 2, 2016	Long C. Hocevar
6		AMY C. HOCEVAR (Ohio Bar #0075510) NICOLE J. GUINTO (Ohio Bar #0089319)
7		DANA C. BARRAGATE (Ohio Bar #0065748)
8		Federal Trade Commission 1111 Superior Avenue, Suite 200
9		Cleveland, Ohio 44114
10		Hocevar Phone: (216) 263-3409 Barragate Phone: (216) 263-3402
11		Guinto Phone: (216) 263-3435 Fax: (216) 263-3426
12		ahocevar@ftc.gov
13		nguinto@ftc.gov dbarragate@ftc.gov
14		
15		Local Counsel THOMAS J. SYTA (California Bar #116286)
16	·	Federal Trade Commission 10877 Wilshire Blvd., Suite 700
17		Los Angeles, CA 90024
18		Phone: (310) 824-4343 Fax: (310) 824-4380
19		tsyta@ftc.gov
20		
21		Attorneys for Plaintiff FEDERAL TRADE COMMISSION
22		TEDERAL TRADE COMMISSION
23		*
24		
25		
26		
27		
28		